Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.56 |
| ▸ | LOX | P28300 | 9/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14572440 | 0.80 | HTR6 (0.56) | HTR6LOXLOXL2MAOAALDH1A1 | |
| SCHEMBL9235944 | 0.80 | LOX (0.61) | HTR6LOXLOXL2MAOA | |
| SCHEMBL14502555 | 0.80 | HTR6 (0.56) | HTR6LOXLOXL2MAOATYMS | |
| SCHEMBL4250025 | 0.80 | HTR6 (0.56) | HTR6LOXLOXL2MAOATYMS | |
| SCHEMBL7132351 | 0.80 | L3MBTL1 (0.46) | LOXALDH1A1HSD17B10TDP1KMT2A | |
| Hydrochloric Acid SCHEMBL27583302 | 0.78 | LOX (0.54) | HTR6LOXLOXL2MAOATYMS | |
| (Phenylsulfonyl)Benzene SCHEMBL27510910 | 0.78 | HTR6 (0.82) | HTR6LOXLOXL2MAOAALDH1A1 | |
| SCHEMBL8779785 | 0.76 | ALDH1A1 (0.80) | HTR6LOXALDH1A1HSD17B10TDP1 | |
| SCHEMBL8825214 | 0.76 | LOX (0.61) | HTR6LOXLOXL2MAOA | |
| SCHEMBL9971313 | 0.76 | HTR6 (0.56) | HTR6LOXLOXL2MAOAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110179777-B | Pharmaceutical compositions comprising nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3427728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20200163929-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| CN-110179777-A | Medical composition comprising nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2019-08-30 | — | — | CN | disclosed |
| US-20190224159-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| CN-105142627-B | Pharmaceutical compositions comprising nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2019-06-21 | — | — | CN | disclosed |
| US-10245249-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3427728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | Cardioxyl Pharmaceuticals, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
| EP-0870764-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5736297-A | Positive-working radiation-sensitive mixture and recording material produced therewith | CLARIANT GMBH (DE) | 1998-04-07 | — | — | US | disclosed |
| EP-0819125-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-01-21 | — | — | EP | disclosed |
| US-5594021-A | VASOCONSTRICTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5591761-A | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-07 | — | — | US | disclosed |
| US-5571821-A | CARDIOVASCULAR DISORDERS TO MODULATE ENDOTHELIN, HYPOTENSIVE AGENTS AND VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1996031492-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | HTR6 372/4885LOX 436/4885LOXL2 772/4885 |
| US-10245249-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | HTR6 372/4885LOX 436/4885LOXL2 772/4885 |
| US-20200163929-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | TNNT2, TNNI3, NQO1 | HTR6 372/4885LOX 436/4885LOXL2 772/4885 |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | HTR6 372/4885LOX 436/4885LOXL2 772/4885 |
| US-20190224159-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | TNNT2, TNNI3, NQO1 | HTR6 372/4885LOX 436/4885LOXL2 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.